You are here

  • Home
  • Archive
  • Volume 69, Issue 6
  • RSPO2 abnormal transcripts result from read-through in liver tumours with high ß-catenin activation and CTNNB1 mutations

Article info

Article menu
Download PDFPDF
PostScript
Letter
RSPO2 abnormal transcripts result from read-through in liver tumours with high ß-catenin activation and CTNNB1 mutations

Authors

  • Quentin Bayard Centre de Recherche des Cordeliers, Inserm, Paris, France Université de Paris, Sorbonne Université, Paris, France PubMed articlesGoogle scholar articles
  • Jean-Charles Nault Centre de Recherche des Cordeliers, Inserm, Paris, France Université de Paris, Sorbonne Université, Paris, France Hepatology Department, Hopital Jean Verdier, APHP, Université Paris 13, Bondy, France PubMed articlesGoogle scholar articles
  • Jessica Zucman-Rossi Centre de Recherche des Cordeliers, Inserm, Paris, France Université de Paris, Sorbonne Université, Paris, France Oncology Department, Hopital Européen Georges Pompidou, APHP, Paris, France PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Jessica Zucman-Rossi, Centre de Recherche des Cordeliers, Paris 75006, France; jessica.zucman-rossi{at}inserm.fr
View Full Text

Citation

Bayard Q, Nault J, Zucman-Rossi J
RSPO2 abnormal transcripts result from read-through in liver tumours with high ß-catenin activation and CTNNB1 mutations
Gut 2020;69:1152-1153.

Publication history

  • Received May 13, 2019
  • Revised May 20, 2019
  • Accepted May 20, 2019
  • First published June 1, 2019.
Online issue publication 
June 09, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.